Zhu Xin-peng, Li Hong, Liu Hong-wei, Yuan Yuan, Liu Chun-hua, Zhu Qian, Cui Wei-guo, Wang Zhe
Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Dec;29(12):1181-4.
To study the correlation between genotype drug resistance and CD(4)(+) T-lymphocyte of AIDS patients who received antiretroviral treatment in Henan province.
Several indicators were studied through questionnaires and whole blood was collected to analyze CD4+ T-lymphocyte as well as the virus load. In-House technique was used to detect the genotype drug resistance.
32.21% and 29.17% of the patients were identified as genotype drug resistant to AIDS when used first and second generation medicine schemes but the improvement (P = 0.7538) of disease process was not influenced much. However, if the genotype drug resistance of patients with HAART last longer than two years (33.20%) or patients with HAART less than one year (18.97%), a greater impact on the improvement was noticed. Age (OR = 0.68) and the interval on distribution of medicines (OR = 1.93) had a great impact on the improvement with the genotype drug resistance through logistic regression analysis. Medicine scheme (OR = 0.51), genotype drug resistance (OR = 3.20) and the rate of regular dose in a month (OR = 0.51) all had a great impact on the improvement to CD4+ T-lymphocyte by logistic regression analysis.
Part of HIV/AIDS patients showed resistant to genotype drugs in Henan province, suggesting that we must reinforce the surveillance on HAART and program on drug administration to the patients, in order to increase the number of CD4+ T-lymphocyte so as to avoid the development of drug resistance.
研究河南省接受抗逆转录病毒治疗的艾滋病患者基因型耐药性与CD4+T淋巴细胞之间的相关性。
通过问卷调查研究多项指标,并采集全血分析CD4+T淋巴细胞以及病毒载量。采用内部技术检测基因型耐药性。
在使用第一代和第二代药物方案时,分别有32.21%和29.17%的患者被鉴定为对艾滋病有基因型耐药性,但疾病进程的改善情况(P = 0.7538)受影响不大。然而,如果接受高效抗逆转录病毒治疗(HAART)时间超过两年的患者(33.20%)或接受HAART时间少于一年的患者(18.97%)出现基因型耐药性,则对病情改善有较大影响。通过逻辑回归分析,年龄(OR = 0.68)和药物分布间隔(OR = 1.93)对基因型耐药性的病情改善有很大影响。药物方案(OR = 0.51)、基因型耐药性(OR = 3.20)和一个月内规律服药率(OR = 0.51)通过逻辑回归分析对CD4+T淋巴细胞的改善均有很大影响。
河南省部分HIV/AIDS患者对基因型药物耐药,提示必须加强对HAART的监测及患者给药方案规划,以增加CD4+T淋巴细胞数量,避免耐药性的发生。